Sugi Predict

Sugi Predict / Targets / DPP8

DPP8

Dipeptidyl peptidase 8 · Q6V1X1 · DPP8 on Sugi Atlas →

103,382 patent compounds predicted against DPP8, 47,509 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL295447 SCHEMBL295447 0.71 17/20
SCHEMBL295843 SCHEMBL295843 0.70 17/20
SCHEMBL294677 SCHEMBL294677 0.69 17/20
SCHEMBL294679 SCHEMBL294679 0.68 17/20
SCHEMBL294712 SCHEMBL294712 0.68 17/20
SCHEMBL293476 SCHEMBL293476 0.67 17/20
SCHEMBL294870 SCHEMBL294870 0.54 17/20
SCHEMBL293795 SCHEMBL293795 0.69 16/20
SCHEMBL145916 SCHEMBL145916 0.63 16/20
Talabostat Talabostat (SCHEMBL393024) 1.00 15/20
SCHEMBL296101 SCHEMBL296101 0.68 15/20
SCHEMBL295145 SCHEMBL295145 0.66 15/20
SCHEMBL293256 SCHEMBL293256 0.57 15/20
SCHEMBL294237 SCHEMBL294237 0.55 15/20
SCHEMBL294749 SCHEMBL294749 0.54 15/20
SCHEMBL295239 SCHEMBL295239 0.52 15/20
SCHEMBL293681 SCHEMBL293681 0.51 15/20
SCHEMBL294717 SCHEMBL294717 0.51 15/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL294373) 0.50 15/20
SCHEMBL293981 SCHEMBL293981 0.48 15/20

Clinical trials — most relevant to DPP8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats PHASE4COMPLETED
Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors PHASE4UNKNOWN
SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients) PHASE4COMPLETED
The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes PHASE4UNKNOWN
Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas PHASE4COMPLETED
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus PHASE4COMPLETED
Correlation Between Plasma- and Endothelial DPP-4 Activity PHASE4COMPLETED
Incretins in Impaired Fasting Glucose PHASE4COMPLETED
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes PHASE3COMPLETED
Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients PHASE3ENROLLING_BY_INVITATION
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes PHASE3COMPLETED
Sitagliptin and Endothelial Dysfunction PHASE3UNKNOWN
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients PHASE3UNKNOWN
Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan PHASE2/PHASE3COMPLETED
Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis PHASE3COMPLETED
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency PHASE2COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics PHASE2COMPLETED
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus PHASE1COMPLETED
The Incretin Effect in Patients With Kidney Impairment nanCOMPLETED
Influence of DPP-4 on Inflammatory Parameters in Diabetics: Gender Aspects nanUNKNOWN
DPP4 Activity, Microvascular Reactivity and Inflammation nanCOMPLETED
Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure nanCOMPLETED
Emulation of the SOUL Diabetes Trial in Healthcare Claims nanCOMPLETED
Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding nanCOMPLETED
Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas nanCOMPLETED
The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation nanUNKNOWN
Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database nanUNKNOWN
Empa PASS on Urinary Tract Malignancies nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DPP8 binder may also engage these)

ProteinNameSimilarity
Q80YA7 — 1.000 Q80YA7 →
A0A2R8QP51 — 0.984 A0A2R8QP51 →
Q338C0 — 0.982 Q338C0 →
Q5ZKL5 — 0.978 Q5ZKL5 →
Q84LM4 — 0.976 Q84LM4 →
Q8VZF3 — 0.976 Q8VZF3 →
Q8C0L9 — 0.976 Q8C0L9 →
Q80VJ4 — 0.975 Q80VJ4 →
Q5HZA6 — 0.975 Q5HZA6 →
Q4J6C6 — 0.975 Q4J6C6 →
Q8BTI9 — 0.974 Q8BTI9 →
Q8N608 — 0.974 Q8N608 →
C1FZL3 — 0.974 C1FZL3 →
C0NUQ8 — 0.974 C0NUQ8 →
A6RBI0 — 0.974 A6RBI0 →
Q10MJ1 — 0.974 Q10MJ1 →
Q9ZV48 — 0.974 Q9ZV48 →
Q95K79 — 0.974 Q95K79 →
Q8BVG4 — 0.974 Q8BVG4 →
Q5ZJM3 — 0.974 Q5ZJM3 →
Q32N48 — 0.974 Q32N48 →
Q0IXP9 — 0.973 Q0IXP9 →
Q8GTR4 — 0.973 Q8GTR4 →
A7EQZ1 — 0.973 A7EQZ1 →
Q0WUI9 — 0.973 Q0WUI9 →
C0S7H1 — 0.973 C0S7H1 →
Q96BT7 — 0.973 Q96BT7 →
Q8N1G2 — 0.973 Q8N1G2 →
P11832 — 0.973 P11832 →
Q92503 — 0.972 Q92503 →